熱門資訊> 正文
Avalyn Pharma报告第一季度业绩
2026-06-03 19:39
- Avalyn Pharma press release (AVLN): Q1 net loss was $26.9 million for the first quarter of 2026, as compared to $17.5 million for the first quarter of 2025.
- Cash, cash equivalents, and marketable securities were $123.1 million as of March 31, 2026.
More on Avalyn Pharma Inc.
- Avalyn Pharma Begins IPO Process For Pulmonary Fibrosis Pipeline
- Lung disease drug developer Avalyn surges on public debut
- Avalyn Pharma prices $300M IPO at $18 per share
- Historical earnings data for Avalyn Pharma Inc.
- Financial information for Avalyn Pharma Inc.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
